EGPI Firecreek, Inc. (OTC Bulletin Board: EFIR) reached up 66.67% in morning trading to $.015 with 2M shares traded. EGPI Firecreek, Inc.'s business and acquisition strategy is focused on both the vertical integration of enterprises serving the D.O.T. Construction and Intelligent Traffic System markets through South Atlantic Traffic, Inc. (SATCO) alongside its wholly owned subsidiary M3 Lighting, Inc. (M3), and on oil and gas production with an emphasis on acquiring existing fields with proven reserves, the rehabilitation of potentially high throughput oilfields, resource properties and inventories, through its wholly owned subsidiary Energy Producers, Inc. (Energy Producers) and for oil and gas servicing business through its wholly owned subsidiary Chanwest Resources, LLC (CWR). EGPI Firecreek, Inc. is also looking to expand into alternative energy sources as well as industries in the energy field. EGPI Firecreek, Inc. (OTCBB: EFIR) is pleased to announce that its wholly owned subsidiary, Terra Telecom, Inc. , was selected to design and deploy an advanced communications network for Risk Enterprise Management (REM), an insurance risk management company whose communications are its pulse and lifeblood in serving its customers.
Spencer Pharmaceutical Inc. (Pink Sheets: SPPH) reached up 43.48% in morning trading to $.33 with 2M shares traded. Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome. Spencer Pharmaceutical Inc. (PINKSHEETS: SPPH) announced today that it has formalized the buyout offer with the Al-Dorra Group as a successful results of meetings held in Montreal, Canada over the past week.
EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) reached up 50% in morning trading to $1.05 with 2M shares traded. EpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of cancer and pain. The Company's lead product is Ceplene, which has been granted full marketing authorization by the European Commission for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission. The Company has two oncology drug candidates currently in clinical development that were discovered using in-house technology and have been shown to act as vascular disruption agents in a variety of solid tumors. The Company's pain portfolio includes EpiCept NP-1, a prescription topical analgesic cream in late-stage clinical development designed to provide effective long-term relief of pain associated with peripheral neuropathies. EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) today announced the results of a new analysis supporting Ceplenes (histamine dihydrochloride) favorable impact on overall survival and its activity with interleukin-2 (IL-2). Ceplene is approved in the European Union for the maintenance of first remission in patients with Acute Myeloid Leukemia (AML) in conjunction with low dose IL-2.
Medistem Inc. (Pink Sheets: MEDS) reached up 100% in morning trading to $.32 with 160K shares traded. Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell being developed for critical limb ischemia. Medistem Inc. (PINKSHEETS: MEDS) announced today peer-reviewed publication of its data on what is believed to be the first "combination therapy" adult stem cell protocol for spinal cord injury. The patient treated, who was 29 years old at the time, suffered a spinal cord injury resulting from an airplane crash on May 13th of 2008. He had no walking ability, intermittent pain and loss of sexual function. The patient was injected with a combination universal donor stem cell therapy in November of 2008, and January and July of 2009. A gradual improvement was observed subsequent to each administration of stem cells.
For a detailed quote on any of the following companies, or to read the full news articles visit PennyTrader.com
About PennyTrader.com
PennyTrader.com is a financial and investor relations website committed to covering the microcap market space including Pink Sheets and OTC Bulletin Board and sub-$5 big board stocks. We strive to provide you with the best stocks alerts in the market! We focus on OTCBB, OTC, penny stocks, sub-$5 big board stocks, and timely stocks picks and alerts. Our goal is to inform you of the HOTTEST stocks in the market before they move. Our staff has years experience in the stock market, and we are confident that you’ll be impressed with the results of our stock picks! If you wish to feature your organization on our website then you can contact us at publisher@pennytrader.com.
Disclosure: PennyTrader.com and affiliates have been compensated ten thousand dollars by a third party (IAB Media) for this current SPPH email promotion.
PennyTrader.com is not a registered investment advisers or broker/dealer. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this press release is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the micro cap companies covered and the potential lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. For our full disclaimer go to CLICK HERE
